Capecitabine versus 5-FU in metastatic colorectal cancer: Considerations for treatment decision-making

Community Oncology

Volumn 3, Issue 1, 2006, Pages 19-27

  Pelusi, Jody ^a,b,c  

^a Arizona Oncology Associates   (United States)

^b University of Phoenix ^*  (United States)

^c GRAND CANYON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PHENYTOIN; WARFARIN;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DECISION MAKING; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SELF ADMINISTRATION; ELECTROLYTE DISTURBANCE; ENZYME DEFICIENCY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFUSION PUMP; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; REIMBURSEMENT; REVIEW; SIDE EFFECT; STOMATITIS; SYMPTOMATOLOGY; VASCULAR ACCESS;

EID: 31144438662     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70639-8     Document Type: Review

References (70)

1. Franson PJ, Lapka DV. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer. Clin J Oncol Nurs 2005;9:55-60.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487.
3. Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs 2005;9:31-44.
4. American Cancer Society. Cancer Facts & Figures 2005. Available at: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed June 9, 2005.
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.1.2006: Colon Cancer. Available at: http://www. nccn.org/ professionals/physician_gls/PDF/colon.pdf. Accessed November 7, 2005.
6. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416-421.
7. Sternberg CN, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs 2004;8(suppl 1): S4-S15.
8. Vega-Stromberg T. Advances in colon cancer chemotherapy: nursing implications. Home Health Nurse 2005;23:154-164.
9. Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 2004;8(suppl 1):S63-S71.
10. Medication sheets for patients. Oral chemotherapy: capecitabine (Xeloda). Clin J Oncol Nurs 2003;7:47-48.
11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
12. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
14. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
15. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
16. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
17. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1998;7:1419-1426.
18. de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
19. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
20. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bi-monthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347.
21. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 3602.
22. th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 1022.
23. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bi-monthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-1342.
24. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
25. Cheeseman SL, Joel SP, Chester JD, et al. A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-399.
26. Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 2002;40:957-964.
27. Andre T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4: preliminary results of the randomized Optimox study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 1016.
28. th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003, Chicago, Ill. Abstract 1181.
29. Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003;21:2703-2707.
30. Eng C, Crane CH, Rosner GL, et al. A phase II study of capecitabine plus oxaliplatin and radiation therapy, XELOX-XRT, in squamous cell carcinoma of the anal canal: a preliminary toxicity analysis. Presented at the 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Fla. Abstract 216.
31. st Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando, Fla. Abstract 3523.
32. st Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando, Fla. Abstract 3515.
33. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 3512.
34. st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 3669.
35. Poorter RL, Bakker PJ, Veenhof CH. Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine. Pharm World Sci 1998;20:45-59.
36. Zhang ZG, Rustum YM. Pharmacologic rationale for fluoropyrimidine- leucovorin combination: biochemical mechanisms. Semin Oncol 1992;19:46-50.
37. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998;16:301-308.
38. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Paper presented at the 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Fla. Abstract 167.
39. Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-3728.
40. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
41. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
42. Twelves C, Wong A, McKendrick J, et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine vs. bolus 5-FU/LV as adjuvant therapy for patients with Dukes' C colon cancer. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando, Fla. Abstract 3521.
43. Twelves C, Wong A, Nowacki MP, et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 3521.
44. st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 3524.
45. st Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando, Fla. Abstract 3507.
46. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 3578.
47. Jordan K, Kellner O, Kegel T, Schmoll H J, Grothey A. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 2004;4:46-50.
48. th Annual Meeting of the American Society of Clinical Oncology - June 5-8, 2004. Abstract 3534.
49. Burris HA, Kalman L, Bertoli L, et al. Continuous flat-dose capecitabine plus weekly irinotecan: an alternative first-line treatment for metastatic colorectal cancer (MCRC). Presented at the 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Fla. Abstract 229.
50. Patt YZ, Lin J, Liebman J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (MCRC). Presented at the 2004 Gastrointestinal Cancers Symposium. Abstract 228. Available at: www.asco.org/ac/1,1003,_12-002636-00_18-0027-00_19-00463,00.asp. Accessed November 7, 2005.
51. th Annual Meeting of the American Society of Clinical Oncology; June 5-8,2004, New Orleans, La. Abstract 8120.
52. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 3610.
53. Jonker DJ, Vincent M, Kerr I, et al. Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC). Presented at the 2004 Gastrointestinal Cancers Symposium. Abstract 212. Available at: http://www.asco.org/ac/1,1003,_12-002634-00_18-0027,00.asp. Accessed November 7, 2005.
54. th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 1297.
55. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 2555.
56. th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 3050.
57. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-1312.
58. Xeloda [package insert]. Nutley, NJ: Roche Laboratories Inc; 2005.
59. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt) 1999;13:17-21.
60. Morrison GB, Bastian A, Dela RT, Diasio RB, Takimoto CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997;24:83-88.
61. Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity: screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997;696:183-191.
62. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003;9:3021-3028.
63. 13C-uracil breath test. Clin Cancer Res 2004;10:2652-2658.
64. Povoski SP. Long-term venous access. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 9th ed. New York, NY: CMP United Business Media; 2005:935-946.
65. Buroker TR, O'Connell MJ, Wieand, HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12;14-20.
66. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004;104:439-456.
67. Iversen LH, Thorlacius-Ussing O. Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002;87:402-408.
68. Levine MN, Lee AY. Treatment of venous thrombosis in the cancer patient. Acta Haematol 2001;106:81-87.
69. Bona RD. Central line thrombosis in patients with cancer. Curr Opin Pulm Med 203;9:362-366.
70. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.